Table 1
Open in new tab

Completed trials of intensified anticoagulant therapy vs. standard dose thromboprophylaxis in hospitalized patients with COVID-19

TrialCOVID-19 populationExperimental treatmentaMajor thrombosisMajor bleedingMortality
NIH multiplatform trial:12,13 ATTACC/ACTIV-4a/REMAP-CAPNon-critically ill (n = 2219)Therapeutic LMWH/UFH1.4% vs. 2.7%b1.9% vs. 0.9%b7.3% vs. 8.2%c
Critically ill in ICU (n = 1074)Therapeutic LMWH/UFH5.7% vs. 10.3%b3.1% vs. 2.4%c35.7% vs. 34.7%c
INSPIRATION14Critically ill in ICU (n = 562)Intermediate dose enoxaparin (1 mg/kg daily)3.3% vs. 3.5%c (VTE)2.5% vs. 1.4%c43.1% vs. 40.9%c
ACTION (NCT04394377)15Elevated D-dimer (n = 615)Rivaroxaban 20 mg daily (stable patients) or enoxaparin 1 mg/kg twice daily (unstable patients)4.0% vs. 6.0%c (VTE)3.0% vs. 1.0%c11% vs. 8%c
TrialCOVID-19 populationExperimental treatmentaMajor thrombosisMajor bleedingMortality
NIH multiplatform trial:12,13 ATTACC/ACTIV-4a/REMAP-CAPNon-critically ill (n = 2219)Therapeutic LMWH/UFH1.4% vs. 2.7%b1.9% vs. 0.9%b7.3% vs. 8.2%c
Critically ill in ICU (n = 1074)Therapeutic LMWH/UFH5.7% vs. 10.3%b3.1% vs. 2.4%c35.7% vs. 34.7%c
INSPIRATION14Critically ill in ICU (n = 562)Intermediate dose enoxaparin (1 mg/kg daily)3.3% vs. 3.5%c (VTE)2.5% vs. 1.4%c43.1% vs. 40.9%c
ACTION (NCT04394377)15Elevated D-dimer (n = 615)Rivaroxaban 20 mg daily (stable patients) or enoxaparin 1 mg/kg twice daily (unstable patients)4.0% vs. 6.0%c (VTE)3.0% vs. 1.0%c11% vs. 8%c

ICU, intensive care unit; LMWH, low molecular weight heparin; NIH, National Institutes of Health; UFH, unfractionated heparin; VTE, venous thrombo-embolism.

a

Control treatment was an approved prophylactic dose of UFH or LMWH.

b

P-value or confidence interval not reported.

c

Not significant.

Table 1
Open in new tab

Completed trials of intensified anticoagulant therapy vs. standard dose thromboprophylaxis in hospitalized patients with COVID-19

TrialCOVID-19 populationExperimental treatmentaMajor thrombosisMajor bleedingMortality
NIH multiplatform trial:12,13 ATTACC/ACTIV-4a/REMAP-CAPNon-critically ill (n = 2219)Therapeutic LMWH/UFH1.4% vs. 2.7%b1.9% vs. 0.9%b7.3% vs. 8.2%c
Critically ill in ICU (n = 1074)Therapeutic LMWH/UFH5.7% vs. 10.3%b3.1% vs. 2.4%c35.7% vs. 34.7%c
INSPIRATION14Critically ill in ICU (n = 562)Intermediate dose enoxaparin (1 mg/kg daily)3.3% vs. 3.5%c (VTE)2.5% vs. 1.4%c43.1% vs. 40.9%c
ACTION (NCT04394377)15Elevated D-dimer (n = 615)Rivaroxaban 20 mg daily (stable patients) or enoxaparin 1 mg/kg twice daily (unstable patients)4.0% vs. 6.0%c (VTE)3.0% vs. 1.0%c11% vs. 8%c
TrialCOVID-19 populationExperimental treatmentaMajor thrombosisMajor bleedingMortality
NIH multiplatform trial:12,13 ATTACC/ACTIV-4a/REMAP-CAPNon-critically ill (n = 2219)Therapeutic LMWH/UFH1.4% vs. 2.7%b1.9% vs. 0.9%b7.3% vs. 8.2%c
Critically ill in ICU (n = 1074)Therapeutic LMWH/UFH5.7% vs. 10.3%b3.1% vs. 2.4%c35.7% vs. 34.7%c
INSPIRATION14Critically ill in ICU (n = 562)Intermediate dose enoxaparin (1 mg/kg daily)3.3% vs. 3.5%c (VTE)2.5% vs. 1.4%c43.1% vs. 40.9%c
ACTION (NCT04394377)15Elevated D-dimer (n = 615)Rivaroxaban 20 mg daily (stable patients) or enoxaparin 1 mg/kg twice daily (unstable patients)4.0% vs. 6.0%c (VTE)3.0% vs. 1.0%c11% vs. 8%c

ICU, intensive care unit; LMWH, low molecular weight heparin; NIH, National Institutes of Health; UFH, unfractionated heparin; VTE, venous thrombo-embolism.

a

Control treatment was an approved prophylactic dose of UFH or LMWH.

b

P-value or confidence interval not reported.

c

Not significant.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close